NCT00044733已完成2 期
A Dose-Finding Study of the Safety of Gemtuzumab Ozogamicin as Single Agent Treatment of Patients With Relapsed Acute Myelogenous Leukemia After Autologous or Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Wyeth is now a wholly owned subsidiary of Pfizer13 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2000年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
- 试验地点
- 13
研究概览
简要总结
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose. A secondary objective is to assess efficacy in terms of the number of patients attaining a complete (CR) or morphological (CRp) remission.
研究设计
- 研究类型
- Interventional
- 盲法
- None
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with CD33+ AML who have experienced relapse after autologous or allogeneic HSCT. Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33 positive, based on local laboratory criteria (Patients with history of MDS pretransplant will be eligible if their proportion of myeloblasts by marrow aspirate exceeds 5% at time of evaluation for Gemtuzumab Ozogamicin treatment)
- •The patient must be greater than or equal to 60 days post-HCST
- •Patients of all ages may be entered in this study
排除标准
- •Peripheral white blood count (WBC) greater than or equal to 30,000/uL at the time of initial Gemtuzumab Ozogamicin administration. (In order to reduce the peripheral blood count, patients may be treated with Hydroxyurea. Hydroxyurea must be discontinued 24 hours prior to Gemtuzumab Ozogamicin administration.)
- •Known active central nervous system (CNS) or testicular leukemia at time of study entry.
- •Prior therapy with anti-CD33 antibodies.
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT00037583Wyeth is now a wholly owned subsidiary of Pfizer69
已完成
2 期
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT00037596Wyeth is now a wholly owned subsidiary of Pfizer
撤回
2 期
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaNCT01548911Wake Forest University Health Sciences
已完成
1 期
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT03900949Uma Borate21
Approved For Marketing
不适用
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaNCT01869803Wake Forest University Health Sciences